Seamless Neurology Olive AI Replacement with Klivira

As neurology practices navigate the discontinuation of Olive AI's prior authorization solutions, maintaining continuity for critical treatments like MS DMTs and CGRP biologics is paramount. Klivira offers a robust, specialized platform for seamless neurology Olive AI replacement.

Revenue cycle leaders and prior authorization coordinators in neurology face unique challenges, from the high volume of specialty drug PAs to complex documentation for advanced imaging and disease-modifying therapies. The need for a reliable, efficient prior authorization automation platform is critical, especially when transitioning from a previous vendor like Olive AI. Klivira provides a clear migration path, ensuring your neurology practice maintains operational efficiency and patient access.

Addressing the Unique Demands of Neurology Prior Authorization

Neurology prior authorization is characterized by high-cost specialty drugs, advanced diagnostics, and chronic treatment management. Our platform is designed to handle complex PA categories such as MS disease-modifying therapies (e.g., ocrelizumab, natalizumab), Alzheimer's disease therapeutics (e.g., lecanemab), CGRP migraine prevention biologics (e.g., erenumab), and advanced imaging like amyloid PET, all while adhering to AAN guidelines.

Migrating from Olive AI: Ensuring Business Continuity for Neurology

For neurology practices previously reliant on Olive AI for prior authorization, a smooth transition is essential to prevent treatment delays and revenue cycle disruptions. Klivira specializes in facilitating migrations from legacy systems, ensuring your existing data, workflows, and payer connections are rapidly re-established. Our team works closely with your IT and revenue cycle departments to minimize downtime and ensure continuous patient care for high-volume neurology PAs.

Key Prior Authorization Triggers in Neurology

MS disease-modifying therapies (e.g., Ocrevus, Tysabri, Kesimpta)
Alzheimer's anti-amyloid antibodies (e.g., Leqembi, Kisunla)
CGRP monoclonal antibodies for migraine prevention (e.g., Aimovig, Ajovy, Emgality)
Botox for chronic migraine, spasticity, dystonia
Advanced imaging: Brain MRI, MR angiography, amyloid PET
Neuromodulation: Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS)

Streamlining EMR Integration and Payer Connectivity for Neurology

Klivira integrates directly with major EMR systems using standards like SMART on FHIR, ensuring neurology-specific order types and clinical documentation are seamlessly captured. We connect to payer portals and leverage electronic prior authorization (ePA) channels like X12 278 and NCPDP SCRIPT, reducing manual data entry for MS DMTs, CGRP biologics, and other high-volume neurology treatments. This ensures that documentation requirements for AAN guidelines are met efficiently.

Optimizing Workflow for Chronic Neurology Treatments and Re-authorizations

Many neurology conditions require ongoing treatment and periodic re-authorization, such as MS DMTs and Botox for chronic migraine. Klivira automates the tracking and submission of re-authorizations, including managing MRI monitoring requirements for drugs like anti-amyloid antibodies. Our platform proactively identifies step therapy requirements and common denial reasons like amyloid biomarker confirmation gaps or chronic migraine criteria, helping your team secure approvals faster.

Frequently asked questions

How does Klivira specifically handle prior authorizations for MS disease-modifying therapies?

Klivira's platform incorporates AAN-guideline-aware step-therapy logic, automating the collection of necessary documentation such as MS diagnosis (McDonald criteria), EDSS scores, relapse history, and prior DMT trials. This streamlines the PA process for high-efficacy agents like ocrelizumab or natalizumab, addressing common payer requirements.

What is involved in migrating prior authorization data and workflows from Olive AI for a neurology practice?

Our migration process involves a thorough assessment of your current Olive AI setup, including payer connections and specific neurology PA workflows. We then work to transfer relevant patient and authorization data, reconfigure payer portal access, and integrate with your EMR, ensuring minimal disruption to your neurology PA operations during the transition.

Does Klivira support prior authorization for new Alzheimer's treatments like lecanemab?

Yes, Klivira supports prior authorization for Alzheimer's anti-amyloid antibodies like lecanemab. Our platform automates the documentation required for these therapies, including amyloid confirmation (PET or CSF), MRI for ARIA screening, and APOE genotype, ensuring compliance with payer-specific protocols and reducing denial risks.

How does Klivira address common denial reasons for neurology prior authorizations?

Klivira's system is designed to proactively address common neurology PA denial reasons, such as step therapy requirements for MS DMTs or CGRP migraine prevention, amyloid biomarker confirmation gaps for AD therapies, and incomplete chronic migraine criteria for Botox. Our intelligent workflows guide users to provide complete documentation upfront.

Can Klivira integrate with our existing EMR for neurology order entry and documentation?

Absolutely. Klivira offers robust integration capabilities with leading EMR systems via SMART on FHIR, allowing for seamless data exchange. This ensures that neurology-specific order types for drugs, imaging, and procedures are automatically populated, reducing manual entry and improving accuracy for prior authorization submissions.